Figures 2 and 3 show the macular thickness and BCVA profiles of patients in the CMO and non-CMO groups, respectively.
For statistical analysis, paired t-test was used to test for significant difference in mean macular thickness and BCVA between baseline and at 16 weeks for both the CMO and non-CMO groups.
Mean macular thickness in the CMO group was significantly thicker than the non-CMO group by 56 μm (95% CI: [36, 77]; p < 0.001).
Similarly, baseline BCVA in the CMO group was 0.92 ± 0.66; in the non-CMO group, it was 0.98 ± 0.59.
At baseline, mean macular thickness in the CMO group was 273 ± 24 μm; in the non-CMO group, it was 259 ± 21 μm.
Mean BCVA in the non-CMO group was significantly less by 0.45 compared to the CMO group (95% CI: [-0.71,-0.19]; p < 0.001) by 16 weeks postoperatively.
Furthermore, about 94% of non-CMO patients ended with BCVA of 0.3 or better, compared to only 38% in the CMO group.
In the CMO group, mean BCVA (in logarithm of minimum angle of resolution) improved modestly from 0.92 ± 0.66 to 0.66 ± 0.41 at week 16; while in the non-CMO group, mean BCVA improved markedly from 0.98 ± 0.59 to 0.21 ± 0.13.
In the CMO group, mean macular thickness (±SD) increased sharply by 56 μm from 273 ± 24 μm at baseline to 329 ± 31 μm at 16 weeks; whereas in the non-CMO group, macular thickness showed a slight increase of 14 μm from 259 ± 21 μm to 272 ± 20 μm.
Since the patterns of visual improvement dependency on change in macular thickness for the CMO and non-CMO group across four time points may be complex, we explored the data graphically using the scatter plot and the heat plot.
In the non-CMO group, mean BCVA decreased substantially to 0.21 ± 0.13.
